Genmab’s DARZALEX Sales Hit $3.96 Billion in Q1 2026—Royalties Set for Significant Boost

Blockbuster First Quarter: DARZALEX Sales Reach $3.96 Billion

Genmab A/S (NASDAQ: GMAB) reported worldwide net sales of DARZALEX (daratumumab) reached $3.96 billion in the first quarter of 2026, according to numbers released today by Johnson & Johnson (Janssen Biotech). The U.S. market pulled in $2.21 billion, while the rest of the world delivered $1.76 billion, underlining the global demand for this key oncology drug.

Royalties Position Genmab for Accelerated Revenue Growth

Genmab receives royalties on all global sales of DARZALEX, covering both intravenous and subcutaneous formulations (the latter sold as DARZALEX FASPRO® in the U.S.). With net trade sales approaching $4 billion this quarter alone, royalty streams are expected to meaningfully reinforce Genmab’s revenue base. This underscores how Genmab’s licensing strategy—putting development, manufacturing, and commercialization in J&J’s hands—continues to pay off for the Danish biotech leader.

Sustained Expansion Across U.S. and International Markets

Sales distribution for Q1 2026 indicates a robust performance in both developed and emerging markets. U.S. sales comprised 55.7% of the total, while international markets contributed a strong 44.3%. This balanced demand highlights DARZALEX’s entrenched presence in cancer treatment guidelines worldwide.

Pipeline Strength and Royalties Provide Strategic Flexibility

With eight approved antibody medicines and a growing late-stage clinical pipeline, Genmab is strategically leveraging its royalty revenue to power innovation. The company’s diverse research into bispecific antibodies, ADCs, immune-modulating antibodies, and next-gen modalities suggests that future royalty surges are likely if pipeline progress continues.

Takeaway: Investors Should Watch for Continued Growth and Royalty Upside

For stakeholders, the key insight is Genmab’s ability to convert scientific breakthroughs into recurring revenue streams. As DARZALEX sales hit new highs and the pipeline matures, Genmab is positioning itself as a major player in global cancer therapeutics. While future results will depend on both market trends and clinical progress, this quarter’s numbers are strong indicators of persistent growth and financial health.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI